What are the recommended pharmacologic options for smoking cessation, including appropriate dosing, contraindications, and counseling recommendations?

Smoking Cessation Medications

For smoking cessation, start with either combination nicotine replacement therapy (21 mg patch + short-acting NRT like gum/lozenge) OR varenicline as first-line pharmacotherapy, combined with behavioral counseling for at least 12 weeks. 1

Preferred First-Line Options

The two equally preferred primary therapies are:

1. Combination NRT

• Dosing: 21 mg nicotine patch daily PLUS short-acting NRT (gum, lozenge, inhaler, or nasal spray) for breakthrough cravings
• If 21 mg patch is ineffective, escalate to 35 or 42 mg patch 1
• Duration: Minimum 12 weeks, can extend to 6-12 months 1
• Safety: Blood nicotine levels from NRT are significantly lower than from smoking; nicotine toxicity is rare and transient even when used while still smoking 1
• Contraindications: Essentially none—NRT is safe even in pregnancy and cardiac disease when the alternative is continued smoking 2

2. Varenicline

• Dosing titration: 1
  • Days 1-3: 0.5 mg once daily
  • Days 4-7: 0.5 mg twice daily
  • Week 2-12: 1 mg twice daily (if tolerated)
• Start 1-2 weeks before quit date
• Duration: Minimum 12 weeks, extendable to 6-12 months 1
• Efficacy: Most effective single agent (RR 2.24 vs placebo; 25.6% vs 11.1% cessation) 3
• Key contraindication: Brain metastases (seizure risk) 1
• Common side effect: Nausea—particularly important to manage in cancer patients on chemotherapy 1

Both options must be paired with behavioral counseling—this combination is more effective than either alone. 3

Second-Line Option

Bupropion SR ± NRT

Use only after trying both preferred options above 1

• Dosing: 1
  • Days 1-3: 150 mg once daily
  • Day 4 onward: 150 mg twice daily (maximum 300 mg/day)
• Start 1-2 weeks before quit date
• Duration: 7-12 weeks minimum 1
• Contraindications: 1
  • Seizure risk (stroke, brain metastases)
  • MAO inhibitor use (hypertensive reactions)
  • Tamoxifen use
  • Closed-angle glaucoma

Behavioral Counseling Requirements

Minimum 4 sessions during each 12-week pharmacotherapy course: 1

• First session within 2-3 weeks of starting medication
• Sessions should be 10-30+ minutes (longer is better)
• Delivered by trained staff, tobacco treatment specialist, or via quitline
• Must include skills training, social support, and motivational interviewing 1

Brief advice (3 minutes minimum) from any clinician increases quit rates and should always be provided 1

Follow-Up Schedule

Critical timing: 1

1. Within 2-3 weeks after starting pharmacotherapy (assess efficacy and toxicity)
2. At 12 weeks (end of initial course)
3. At 6 and 12 months if smoke-free

Nicotine withdrawal peaks at 1-2 weeks then subsides—early follow-up is essential to encourage adherence through this period 1

Management of Treatment Failure or Relapse

If patient continues smoking or relapses: 1

1. Continue or resume initial pharmacotherapy, OR
2. Switch to the other preferred option (if on NRT, switch to varenicline or vice versa)
3. Only after trying BOTH preferred options, consider bupropion ± NRT
4. Intensify behavioral therapy with each subsequent attempt
5. Consider extending duration beyond 12 weeks

Dose adjustments are appropriate if clinically indicated—track reduction efforts and switch therapies if progress stalls 1

Neuropsychiatric Safety

Recent large RCT (n=8,058) found no significant increase in neuropsychiatric adverse events with varenicline or bupropion versus nicotine patches or placebo, even in patients with diagnosed psychiatric disorders. 1 However, monitor for development or worsening of depression and suicidal ideation, and discontinue if these occur 1

Special Populations

Cancer patients: Combination NRT or varenicline are preferred; avoid varenicline and bupropion in brain metastases 1

Preoperative patients: Start cessation as far in advance as feasible, but do not delay necessary cancer surgery for smoking cessation 1

Cardiovascular disease: All medications are appropriate; aggressive cessation is critical as smoking is the strongest risk factor for PAD progression and MACE 4

Common Pitfalls to Avoid

• Underdosing NRT: Use adequate doses (21 mg patch minimum, escalate if needed) 1
• Monotherapy when combination is better: Combination NRT outperforms single NRT products 3
• Inadequate duration: Minimum 12 weeks required; many patients benefit from 6-12 months 1
• Pharmacotherapy without counseling: Combination approach doubles success rates 3
• Abandoning treatment after brief slip: Withdrawal peaks at 1-2 weeks; patients may quit after symptoms subside 1